4//SEC Filing
Dube Eric M 4
Accession 0001415889-25-003065
CIK 0001438533other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 8:30 PM ET
Size
9.6 KB
Accession
0001415889-25-003065
Insider Transaction Report
Form 4
Dube Eric M
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
2025-02-03$20.21/sh−50,691$1,024,343→ 430,548 total - Award
Common Stock
2025-01-31+130,000→ 481,239 total - Award
Employee stock option (right to buy)
2025-01-31+260,000→ 260,000 totalExercise: $20.46Exp: 2035-01-31→ Common Stock (260,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F2]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F3]The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F4]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001763494
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 8:30 PM ET
- Size
- 9.6 KB